ZEVRA THERAPEUTICS, INC.

For the period ended Dec 31, 2025. Filed Mar 9, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 9, 2026

ZVRA$11.92-1.8%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets as of December 31, 202, and

CONSOLIDATED BALANCE SHEETS

(in thousands, except share and par value amounts)

	December 31,
	2025	2024
Assets
Current assets:
Cash and cash equivalents	$62,406	$33,785
Securities at fair value, current	128,605	35,711
Accounts and other receivables	23,258	10,509
Prepaid expenses and other current assets	6,998	4,052
Inventories, current	1,740	1,970
Total current assets	223,007	86,027
Securities at fair value, noncurrent	47,879	6,010
Inventories, noncurrent	879	10,999
Property and equipment, net	489	356
Operating lease right-of-use assets	1,212	657
Goodwill	4,701	4,701
Intangible assets, net	6,421	68,993
Other long-term assets	143	384
Total assets	$284,731	$178,127
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable and accrued expenses	$11,598	$25,456
Current portion of operating lease liabilities	419	420
Current portion of discount and rebate liabilities	12,188	5,929
Current portion of income tax payable	13,710	—
Other current liabilities	1,362	2,260
Total current liabilities	39,277	34,065
Long-term debt	61,928	59,504
Warrant liability	9,575	17,804
Income tax payable	7,029	14,431
Operating lease liabilities, less current portion	859	372
Discount and rebate liabilities, less current portion	9,693	7,655
Other long-term liabilities	1,713	4,630
Total liabilities	130,074	138,461
Commitments and contingencies (Note K)
Stockholders' equity:
Preferred stock:
Undesignated preferred stock, $0.0001 par value, 10,000,000 shares authorized, no shares issued or outstanding as of December 31, 2025 or December 31, 2024	—	—
Common stock, $0.0001 par value, 250,000,000 shares authorized, 58,338,319 shares issued and 56,854,781 shares outstanding as of December 31, 2025; 55,246,401 shares issued and 53,670,709 shares outstanding as of December 31, 2024	6	5
Additional paid-in capital	588,458	555,302
Treasury stock, at cost	(10,983)	(10,983)
Accumulated deficit	(422,060)	(505,289)
Accumulated other comprehensive (loss) income	(764)	631
Total stockholders' equity	154,657	39,666
Total liabilities and stockholders' equity	$284,731	$178,127

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.